Occurrence and Minimization of Cysteine Racemization during Stepwise Solid-Phase Peptide Synthesis<sup>1</sup><sup>,</sup><sup>2</sup>
作者:Yongxin Han、Fernando Albericio、George Barany
DOI:10.1021/jo9622744
日期:1997.6.1
suitable additives such as 1-hydroxybenzotriazole (HOBt) or 7-aza-1-hydroxybenzotriazole (HOAt) plus a tertiaryaminebase such as N,N-diisopropylethylamine (DIEA) or N-methylmorpholine (NMM). Under such conditions, the levels of racemization in the model peptide, expressed as the ratio of D:L peptide formed, were in the entirely unacceptable range of 5-33%. However, these levels were in general reduced
α-Ketocarbonyl Peptides: A General Approach to Reactive Resin-Bound Intermediates in the Synthesis of Peptide Isosteres for Protease Inhibitor Screening on Solid Support
highly reactive terminal ketocarbonyls were prone to aldol-type dimerization and could be transferred into stable moieties by oxime formation, reduction to the alcohol, or reductive amination, respectively. The alpha-ketocarbonyl peptides were efficient in nucleophilic addition of C-nucleophiles such as phosphono-ylides and allylsilanes.
α-酮羰基肽是通过金属离子催化的转氨作用从固体支持物上的肽前体生成的。反应在 2 小时内完成,乙醛酸盐作为亲电子试剂,铜 (II) 离子作为催化剂,在 pH 5.5-6.0 的醋酸水溶液缓冲液中。各种天然存在的 α-氨基酸底物产生了一组不同的差异功能化酮。高度反应性的末端酮羰基易于发生羟醛型二聚反应,并且可以分别通过肟形成、还原为醇或还原胺化而转化为稳定的部分。α-酮羰基肽在 C-亲核试剂的亲核加成中是有效的,例如膦酰基内酯和烯丙基硅烷。
Solid-state<sup>17</sup>O NMR in Biological Solids: Efficient<sup>17</sup>O Labeling of Amino Acids and Peptides
A highly effective labeling method for 17O-enriched amino acids and peptides at moderate experimental conditions (Japanese Patent 2006-8666) has been presented, which has enabled us to readily carry out solid-state 17O NMR experiments in almost all amino acids and peptides.
MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE
申请人:Biomarck Pharmaceuticals, Ltd.
公开号:EP2399599A2
公开(公告)日:2011-12-28
Peptides are provided that comprise less than 24 amino acids. The peptides have an amino acid sequence selected from the group consisting of: (a) an amino acid sequence having from 4 to 23 contiguous amino acids of a reference sequence PEPTIDE 1; (b) an amino acid sequence substantially identical to the sequence defined in (a); and (c) a variant of the amino acid sequence defined in (a). Also provided is a non-myristoylated MANS peptide. Various methods of using the peptides are also provided.